SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F

Diabetes, Metabolic Syndrome and Obesity 2019, 12:1001-1012

Published Date: 3 July 2019